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ABSTRACT 23 
Adgrg6 (Gpr126) is an adhesion class G protein-coupled receptor with a conserved role in 24 
myelination of the peripheral nervous system.  In the zebrafish, mutation of adgrg6 also 25 
results in defects in the inner ear: otic tissue fails to down-regulate versican-gene expression 26 
and morphogenesis is disrupted.  We have designed a whole-animal screen that tests for 27 
rescue of both up- and down-regulated gene expression in mutant embryos, together with 28 
analysis of weak and strong alleles.  From a screen of 3120 structurally diverse compounds, 29 
we have identified 68 that reduce versican-b expression in the adgrg6 mutant ear, 41 of 30 
which also restore myelin basic protein gene expression in Schwann cells of mutant 31 
embryos.  Nineteen compounds unable to rescue a strong adgrg6 allele provide candidates 32 
for molecules that may interact directly with the Adgrg6 receptor.  Our pipeline provides a 33 
powerful approach for identifying compounds that modulate GPCR activity, with potential 34 
impact for future drug design. 35 
  36 
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INTRODUCTION 37 
Adgrg6 (Gpr126) is an adhesion (B2) class G protein-coupled receptor (aGPCR) with 38 
conserved roles in myelination of the vertebrate peripheral nervous system (PNS) (reviewed 39 
in (Langenhan et al., 2016; Patra et al., 2014)).  In homozygous loss-of-function adgrg6 40 
zebrafish and mouse mutants, peripheral myelination is severely impaired: Schwann cells 41 
associate with axons, but are unable to generate the myelin sheath, and show reduced 42 
expression of the myelin basic protein (mbp) gene (Glenn and Talbot, 2013; Mogha et al., 43 
2013; Monk et al., 2009; Monk et al., 2011).  Targeted disruption of Adgrg6 in the mouse 44 
results in additional abnormal phenotypes, including limb and cardiac abnormalities, axon 45 
degeneration and embryonic lethality (Monk et al., 2011; Patra et al., 2013; Waller-Evans et 46 
al., 2010).  In humans, mutations in ADGRG6 are causative for congenital contracture 47 
syndrome 9, a severe type of arthrogryposis multiplex congenita (Ravenscroft et al., 2015).  48 
Peripheral nerves from affected individuals have reduced expression of myelin basic protein, 49 
suggesting that the function of ADGRG6 in myelination is evolutionarily conserved from 50 
teleosts to humans (Ravenscroft et al., 2015).  Human ADGRG6 variants have also been 51 
proposed to underlie some paediatric musculoskeletal disorders, including adolescent 52 
idiopathic scoliosis (Karner et al., 2015) (and references within). 53 
 54 
In zebrafish, homozygous loss-of-function adgrg6 mutants exhibit an inner ear defect in 55 
addition to deficiencies in myelination (Geng et al., 2013; Monk et al., 2009).  In the otic 56 
vesicle, the epithelial projections that prefigure formation of the semicircular canal ducts 57 
overgrow and fail to fuse, resulting in morphological defects and ear swelling.  Analysis of 58 
the zebrafish adgrg6 mutant ear shows a dramatic alteration in the expression of genes 59 
coding for several extracellular matrix (ECM) components and ECM-modifying enzymes 60 
(Geng et al., 2013) (Fig. 1A).  Notably, transcripts coding for core proteins of the chondroitin 61 
sulphate proteoglycan Versican, normally transiently expressed in the outgrowing 62 
projections and then down-regulated once projection fusion has occurred, remain highly 63 
expressed in the overgrown and unfused projections of adgrg6 mutants (Geng et al., 2013).  64 
Although Adgrg6 (Gpr126) mRNA is known to be expressed in the mouse ear (Patra et al., 65 
2013), a role in otic development in the mammal has yet to be determined. 66 
 67 
Like all aGPCR members, the zebrafish Adgrg6 receptor consists of a long extracellular 68 
domain (ECD), a seven-pass transmembrane domain (7TM), and a short intracellular 69 
domain (reviewed in (Langenhan et al., 2016)) (Fig. 1B).  The ECD includes a GPCR 70 
autoproteolysis-inducing (GAIN) domain, which incorporates the GPCR proteolytic site 71 
(GPS) and the conserved Stachel sequence (Liebscher et al., 2014; Patra et al., 2014).  72 
Proteolysis at the GPS results in two fragments, an NTF (N-terminal fragment) and a CTF 73 
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(C-terminal fragment), which can remain associated with one another, or may dissociate, the 74 
NTF binding to cell surface or extracellular matrix ligands (Patra et al., 2014; Petersen et al., 75 
2015).  Dissociation of the NTF triggers binding of the Stachel sequence to the 7TM domain, 76 
thereby activating the CTF (Liebscher et al., 2014).  This feature provides a variety of CTF-77 
dependent or -independent signalling capabilities that orchestrate cell adhesion and other 78 
cell-cell or cell-matrix interactions.  For example, during Schwann cell development and 79 
terminal differentiation, the Adgrg6 NTF promotes radial sorting of axons, while the CTF is 80 
thought to signal through a stimulatory Gα subunit (Gαs), leading to elevated cAMP levels 81 
and activated protein kinase A (PKA) to induce transcription of downstream target genes, 82 
such as egr2 and oct6 (Petersen et al., 2015).  Compounds that act to raise intracellular 83 
cAMP levels, such as the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX) 84 
and the adenylyl cyclase activator forskolin, can rescue phenotypic defects in both the inner 85 
ear and PNS in adgrg6 mutants (Geng et al., 2013; Monk et al., 2009).   86 
 87 
Despite the enormous importance of GPCRs as drug targets (Hauser et al., 2017; Sriram 88 
and Insel, 2018; Wootten et al., 2018), adhesion class GPCRs remain poorly characterised, 89 
representing a valuable untapped resource as targets of future therapeutics (Hamann et al., 90 
2015; Monk et al., 2015).  The identification of specific modulators of aGPCR activity is an 91 
essential step for understanding the mechanism of aGPCR function and to inform the design 92 
of new drugs.  Recent successful approaches include the use of Stachel sequence peptides 93 
as aGPCR agonists (Demberg et al., 2017), or synthetic monobodies directed against 94 
domains within the NTF (Salzman et al., 2017).  A promising alternative approach lies in the 95 
potential of unbiased whole-animal screening of small molecules.  In recent years, zebrafish 96 
have emerged as an important tool for in vivo phenotypic screening for new therapeutics 97 
(Brady et al., 2016) and for understanding biological mechanisms (Baxendale et al., 2017; 98 
Richter et al., 2017).  Zebrafish have many advantages for drug discovery: they are a 99 
vertebrate species whose embryos can fit into individual wells of a multiwell plate, facilitating 100 
high-throughput analysis; they generate large numbers of offspring; they can absorb 101 
compounds directly added to the water, and whole-organism screening enables toxicity, 102 
absorption, metabolism and excretion of compounds to be assayed early in the screening 103 
pipeline.   104 
 105 
To date, over one hundred drug screens using different zebrafish disease models have been 106 
conducted, some identifying lead compounds that have subsequently been tested in 107 
mammalian model systems or entered clinical trials (Chowdhury et al., 2013; Griffin et al., 108 
2017; North et al., 2007; Owens et al., 2008) (reviewed in (Baxendale et al., 2017)).  Two 109 
screens have been performed to identify compounds that promote myelination in the central 110 
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nervous system (Buckley et al., 2010; Early et al., 2018).  These studies used live imaging of 111 
Tg(olig2:GFP) or Tg(mbp:eGFP) fluorescent transgenic lines to screen for small molecules 112 
that increase progenitor or myelinating oligodendrocyte cell number.  While elegant in 113 
design, and successful in identifying hit compounds, these screens required the use of 114 
sophisticated and costly high-resolution imaging platforms and relied on detailed quantitative 115 
assays for cell number, techniques that are not available to all labs and are potentially 116 
limiting in scalability and throughput. 117 
 118 
In this study, we have developed an in vivo drug screening assay based on semi-automated 119 
in situ hybridisation (ISH) to identify modulators of the Adgrg6 pathway.  We have used the 120 
otic expression of versican b (vcanb) as an easily-scored qualitative readout to identify 121 
compounds that can reduce vcanb overexpression back to normal levels in a hypomorphic 122 
mutant allele for adgrg6, tb233c.  We used expression of mbp in the posterior lateral line 123 
ganglion of adgrg6tb233c mutants as a secondary screening assay, with the aim of identifying 124 
chemical classes capable of rescuing the expression of both genes, which may thus 125 
represent agonists of the Adgrg6 signalling pathway.  To identify ligands that potentially bind 126 
directly to Adgrg6, we then tested hit compounds for their ability to rescue a strong loss-of-127 
function adgrg6 allele, fr24, which predicts a severely truncated protein.  Several compounds 128 
were unable to rescue adgrg6fr24 mutants, including a group with similar structures from the 129 
gedunin family of compounds.  Compounds able to rescue both alleles include colforsin, a 130 
known activator of adenylyl cyclase, demonstrating proof-of-principle that our screen can 131 
identify compounds that restore GPCR pathway activity downstream of the receptor.  These 132 
alternative assays for both down-regulation and up-regulation of gene expression, combined 133 
with a comparison of rescue in both weak and strong alleles, have facilitated selection of a 134 
strong cohort of hit compounds that can be differentiated by the different screens used.  Our 135 
approach is scalable and can be used to screen additional compound collections.  In 136 
parallel, chemoinformatics analysis of the compound libraries and identified hits has enabled 137 
classification and prioritisation of selected hit compounds. 138 
 139 
  140 
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RESULTS 141 
Choice of markers for an in situ hybridisation-based screen: otic vcanb expression as 142 
a robust readout 143 
We set out to develop a simple assay to identify small molecule modifiers of the Adgrg6 144 
pathway that can be used both to understand Adgrg6 function and to identify compounds 145 
that could inform the design of therapeutics.  To this end, we chose to perform a drug screen 146 
based on in situ hybridisation (ISH), which has the advantage of being a simple, 147 
reproducible assay that can be semi-automated (Baxendale et al., 2012; North et al., 2007).  148 
We selected vcanb expression in the adgrg6 mutant ear for our primary screen.  vcanb has 149 
a number of advantages for screening, including highly localised expression in the otic 150 
vesicle, very strong and reproducible staining intensity in adgrg6 mutant embryos, and a 151 
clear difference between staining in mutant and wild-type embryos at the stage chosen, 152 
making it ideal for manual scoring (Fig. 1A).  We therefore developed a primary screen 153 
seeking compounds that can reduce vcanb levels in adgrg6 mutant embryos and rescue the 154 
mutant phenotype.  We reasoned that, in addition to yielding information for the ear 155 
phenotype, compounds that can rescue vcanb expression may also rescue myelination 156 
defects in the PNS, where expression patterns of genetic markers are more complex and 157 
defects are harder to score. 158 
 159 
We first made a careful comparison of the otic and PNS defects in weak (tb233c) and strong 160 
(fr24) alleles for the adgrg6 mutant (Fig. 1A).  The tb233c allele is a missense mutation 161 
(I963N) in the fourth transmembrane domain of the receptor, whereas the fr24 allele is a 162 
nonsense mutation (L463X), predicting a severely truncated protein lacking the hormone-163 
binding, GAIN, 7TM and C-terminal domains (Geng et al., 2013) (Fig. 1B).  Mutants for both 164 
tb233c and fr24 alleles have the same defect in semicircular canal formation: otic epithelial 165 
projections are enlarged, overgrow, and fail to fuse to form the three pillars that create the 166 
hubs of the semicircular canal ducts (Geng et al., 2013) (Fig. 1A).  Time-lapse imaging using 167 
light-sheet microscopy reveals the dynamics of this process: even when projections make 168 
contact with each other, they fail to adhere as in the wild type.  Instead, projections in the 169 
mutant ear continue to grow, roll around one another as they find space with least 170 
resistance, and fill the otic vesicle with semicircular canal projection tissue (Fig. 1C; Videos 171 
1,2).  In wild-type ears, vcanb is expressed in the growing semicircular canal projections 172 
between 44 and 72 hours post fertilisation (hpf), but is then strongly down-regulated after 173 
fusion; by 4 days post fertilisation (dpf), very little expression is detectable in the ear (Geng 174 
et al., 2013).  By contrast, in adgrg6 mutants, the overgrown and unfused projections in the 175 
developing ear continue to express vcanb at high levels (Geng et al., 2013) (Fig. 1A).  Both 176 
alleles show a dramatically increased level of expression over wild-type embryos, but the 177 
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increase is stronger in the fr24 allele (Fig. 1A).  mRNA for adgrg6 itself is expressed in the 178 
otic vesicle of mutant embryos for both alleles (Geng et al., 2013) (and unpublished data), 179 
but it is not known whether a truncated protein including the CUB and PTX domains is 180 
produced in the fr24 allele.  (Note, however, that some biological activity is retained for a 181 
different truncating mutation, Y782X, in the Adgrg6 NTF (Petersen et al., 2015)). 182 
 183 
In addition to an upregulation of vcanb expression in the ear, the zebrafish adgrg6 mutant 184 
also shows a reduction or loss of expression of the myelin basic protein (mbp) gene in the 185 
PNS (Geng et al., 2013; Monk et al., 2009).  This additional phenotype proved to be very 186 
valuable for our screen design, helping to validate hits and eliminate false positives.  187 
Expression of mbp is present in a complex pattern in wild-type embryos, and shows clear 188 
differences between the two alleles, correlating with the predicted severity of the mutations 189 
(Fig. 1B).  Expression is variably reduced along the posterior (trunk) lateral line nerve in 190 
homozygous mutants for the hypomorphic tb233c allele, but in all individuals there is 191 
consistent absence of staining in cells (presumed Schwann cells) associated with the 192 
posterior lateral line ganglion (PLLg) (Geng et al., 2013) (Fig. 1A, Fig. 1—figure supplement 193 
1).  The fr24 allele lacks nearly all mbp staining along peripheral nerves (Geng et al., 2013) 194 
(Fig. 1A).  Note that expression of mbp in the central nervous system (CNS) is not affected 195 
in either allele, obscuring any reduction of mbp staining in the PNS without performing a 196 
detailed analysis.  This made mbp expression unsuitable for a primary screen, but useful for 197 
a secondary screen of hit compounds identified from the vcanb screen. 198 
 199 
Design of a screening pipeline for compounds that rescue the adgrg6tb233c mutant 200 
phenotype 201 
Our strategy for the screening protocol and analysis pipeline is outlined in Figure 2.  Both the 202 
weak (tb233c) and strong (fr24) alleles of adgrg6 mutants are homozygous viable, enabling 203 
large batches of 100% mutant embryos to be generated for each assay.  We decided to use 204 
the hypomorphic allele (tb233c) in our primary screen, for four main reasons: (1) adult fish 205 
homozygous for the tb233c allele produce a larger number of healthy embryos than adults 206 
homozygous for the fr24 allele; (2) a lower concentration of our positive control compound 207 
IBMX was sufficient to rescue the phenotype in tb233c mutants compared with fr24 mutants 208 
(Geng et al., 2013), suggesting that the tb233c allele might also be easier to rescue with 209 
other compounds in the libraries screened; (3) vcanb expression, although not as 210 
dramatically affected as in fr24, is still robustly over-expressed in the tb233c allele, and (4) 211 
we predicted that any small molecules that interact with the active site of the receptor or act 212 
as allosteric modulators would be missed in a screen using fr24 mutants, which should only 213 
be able to identify compounds acting on targets downstream of the receptor.  By using 214 
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tb233c, we should be able to identify modulators of the pathway acting both downstream 215 
and at the level of the receptor itself. 216 
 217 
Choice of controls 218 
In all assay plates, we included the phosphodiesterase inhibitor IBMX (100 µM) as a positive 219 
control.  We have previously shown that addition of 100 たM IBMX at 60 hpf is optimal for 220 
both down-regulation of vcanb expression and a rescue of projection fusion in the ears of 221 
adgrg6tb233c mutants (Geng et al., 2013).  At this stage of development, the anterior and 222 
posterior projections in the mutant otic vesicle are extended and in close proximity to the 223 
lateral projection, to which they would fuse in the wild type (Fig. 2A).  Compounds from both 224 
libraries are supplied as stocks dissolved in DMSO; we therefore used 1% DMSO as a 225 
negative control.  The nacre (mitfa-/-) strain, which has reduced pigmentation, facilitating 226 
visualisation of ISH staining patterns, was used as an untreated wild-type control.  Three 227 
embryos per well were treated with compounds at 25 µM in E3 medium from 60–90 hpf, 228 
after which they were fixed and analysed for expression of vcanb by whole-mount ISH.  At 229 
the embryonic stage assayed by ISH (90 hpf), expression of vcanb in untreated mutant 230 
embryos is very specific to the ear, making it clearly visible as two dark spots in the head of 231 
each embryo within the well.  All controls gave results as expected in all assay plates tested: 232 
DMSO-treated mutant embryos showed strong otic staining for vcanb, untreated wild-type 233 
embryos showed very little staining in the ear, and IBMX-treated mutant embryos showed 234 
rescued (down-regulated) otic vcanb expression (Fig. 2A). 235 
 236 
Comparison of compound libraries with diverse structures  237 
In order to test a wide range of compounds, we chose to screen two commercial small 238 
molecule libraries.  The Tocriscreen Total library (‘Tocris’) consists of 1120 compounds 239 
representing known bioactive compounds with diverse structures.  The Spectrum Collection 240 
(‘Spectrum’; Microsource Discovery Systems) comprises 2000 compounds, including FDA-241 
approved drugs for repurposing, bioactive compounds and natural products.  Scaffold 242 
analysis of the two libraries highlights the structural diversity present (Fig. 3—figure 243 
supplement 1).  Based on Bemis-Murcko scaffolds (Bemis and Murcko, 1996), the Tocris 244 
library of 1120 compounds has 693 (62%) scaffolds representing a single compound and 245 
only two scaffolds representing more than 10 compounds.  The Spectrum library has 682 246 
scaffolds representing unique chemical structures, but as the library consists of 2000 247 
compounds, the proportion of scaffolds represented by a single molecule (30%) is lower 248 
than for the Tocris library.  Together, the two libraries cover a wide range of chemical space, 249 
with a total of 1540 scaffolds, of which 1134 represent unique compounds.  Scaffold analysis 250 
not only provides a broad overview of the chemical diversity of each library, but can also be 251 
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used to select and analyse groups of similar compounds with interesting structure-activity 252 
relationships.  Compounds were also clustered based on their fingerprint similarity using 253 
Ward’s method of hierarchical agglomerative clustering, which was useful for visualisation 254 
purposes (for dendrograms, see Fig. 3—figure supplement 2). 255 
 256 
Results of the primary screen for reduction of otic vcanb expression levels  257 
To score the efficacy of the compounds in down-regulating vcanb mRNA levels, we used a 258 
scoring system from 0 to 3 (Fig. 3; for details, see the Materials and Methods).  In the 259 
primary screen, each compound was tested against three embryos and the score for each 260 
embryo was added to give a final score out of 9.  The final scores were classified into 261 
different groups according to the thresholds shown in Figure 3B, with the highest degree of 262 
rescue in Category A, representing a combined score no greater than 2.  Completion of the 263 
primary vcanb screen for all 3120 compounds identified 92 (8%) compounds from the Tocris 264 
library and 205 (10%) from the Spectrum library that scored in categories A–C (Fig. 3C,E).  265 
5% of the compounds from each library were found to be either toxic (category F; dead 266 
embryos or severe developmental abnormalities) or potentially corrosive (category G; no 267 
embryos present), while 99 (9%) compounds from Tocris and 269 (13%) from Spectrum 268 
were found to cause incomplete or partial suppression of vcanb expression (category D).  269 
The largest category (E; 2282 compounds from both libraries, 73%), as expected, 270 
represented compounds that had no rescuing or other effect at the concentration used (25 271 
µM).  To visualise the complete set of screening results and to identify any clusters of hit 272 
compounds with similar structures, compounds were displayed as individual data points on a 273 
polar scatterplot (Fig. 3D,F; Fig. 4; interactive version at 274 
https://adlvdl.github.io/visualizations/polar_scatterplot_whitfield_vcanb.html).  Compound 275 
position along the circumference of the plot for each library is based on position on the 276 
respective similarity dendrogram (Fig. 3—figure supplement 2).  Data points that are 277 
clustered along radii of the plot are thus more likely to be structurally similar, although note 278 
that the juxtaposition of different branches of the dendrogram can also place compounds 279 
that differ in structure adjacent to one other.  Due to the wide diversity of scaffolds found in 280 
the Tocris library, less clustering of hit compounds (A–C) can be observed compared with 281 
the molecules in the Spectrum library, where more clusters of compounds in the A–C 282 
categories are evident (Fig. 3D,F). 283 
 284 
Validation of the primary screen: retesting, comparison with control compounds and 285 
analysis of duplicates 286 
Possible hit compounds categorised as A–C were selected and arrayed into cherry-pick 287 
plates, which were tested using the same assay format.  These included all the top hit 288 
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compounds that scored A or B, and a selection of compounds from the lower-scoring C 289 
category (see Materials and Methods).  Specifically, 83 out of the 92 possible hit compounds 290 
from the Tocris library and 145 of the 205 possible hits from the Spectrum library were 291 
retested twice, again with three embryos per well.  By increasing the number of embryos 292 
screened to a total of nine per compound, we aimed to eliminate any false-positive hits that 293 
had an increased average score over these two retests or did not show a clear rescue 294 
(score >7) in any individual test.  In total, 91 compounds from the combined list of hits (29 295 
from Tocris, 62 from Spectrum) that showed consistent rescue of vcanb expression across 296 
the retests were taken forward for secondary assays (Fig. 4G).  297 
 298 
To provide further validation for the hits identified in the primary screen, we used two 299 
approaches.  Firstly, we compared the results of our control compounds to those of similar 300 
compounds present in the screened compound libraries.  The control compound IBMX, a 301 
non-selective phosphodiesterase (PDE) inhibitor, is present in the Spectrum library and was 302 
identified as a hit in the primary screen (Fig. 2A).  The most similar compound to IBMX from 303 
both libraries is 8-methoxymethyl-3-isobutyl-1-methylxanthine (MMPX), a selective PDE-1 304 
inhibitor.  MMPX is present in the Tocris library, but was not identified as a hit in our screen, 305 
most likely due to its selectivity.  In previous work we also used forskolin to raise cAMP 306 
levels and rescue the adgrg6 ear phenotype (Geng et al., 2013), but forskolin requires 307 
different assay conditions with short drug incubation times to avoid toxicity.  Forskolin is 308 
represented in the Tocris library, but was toxic in our screening assay.  The Spectrum 309 
Collection contains two forskolin-related compounds, colforsin and desacetylcolforsin.  310 
Colforsin, a water-soluble derivative of forskolin, was identified as a hit in the primary screen, 311 
and retested positive in all subsequent tests (see also below); it appeared to be less toxic 312 
than forskolin, whereas desacetylcolforsin was toxic at the concentration used.  The 313 
identification of both IBMX and colforsin as hits in the primary screen confirmed that the 314 
assay conditions used were efficient at detecting expected hit compounds. 315 
 316 
Secondly, we compared the scores for all compounds that were duplicated in both 317 
compound libraries.  Chemoinformatics analysis of the Tocris and Spectrum libraries 318 
identified 155 compounds represented in both libraries, 65% of which (100/155) had exactly 319 
the same vcanb score average from the two individual screens.  39 (25%) of the 155 320 
duplicate compounds yielded a vcanb score average that differed by 1–2 units between the 321 
two libraries; 12 (8%) of the compounds yielded a vcanb score average that differed by 3–6 322 
units, while only 4 (3%) compounds had a score average that differed by 7–9 units.  In 323 
summary, 90% (139/155) of the compounds common to both libraries showed similar scores 324 
for the vcanb assay from each library (scores differing by ≤2 units), while 10% (16/155) of 325 
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the compounds resulted in differing levels of vcanb down-regulation between the two 326 
different libraries.  After retesting, the difference between the two vcanb score averages for 327 
nine of these compounds was reduced; however, for seven compounds, the scores between 328 
the two libraries remained significantly different.  These discrepancies could be either due to 329 
differences in compound purity between the two suppliers, or could be due to experimental 330 
error (e.g. in the concentration used, or during the ISH protocol).  In cases where the same 331 
compound was scored as toxic in one assay and not in another, the health condition of the 332 
fish in a particular well could be the underlying reason.  Duplicated compounds have been 333 
included in the data for each library in the polar scatter plots (Figs 3,4).   334 
 335 
The top 91 hit compounds from both libraries (29 from Tocris, 62 from Spectrum) that scored 336 
A–C in all three vcanb assays were combined to give a complete list of 89 unique 337 
compounds, with baicalein and gedunin present in both libraries.  The list covers a wide 338 
spectrum of naturally-derived and synthetic molecules, with known and unknown functions 339 
(Supplementary file 1).  The hit compounds with known functions include calcium channel 340 
blockers, antifungal, anti-inflammatory, antihyperlipidemic, antibacterial and anthelmintic 341 
agents, as well as compounds with known antineoplastic and vasodilatory properties. 342 
 343 
Secondary screen for rescue of mbp expression, and identification of false positives 344 
The two retests for vcanb expression significantly reduced the possibility of false-positive 345 
results due to experimental error (e.g. in the ISH protocol), but the list of hits could still 346 
contain false-positive compounds that may generally inhibit transcription.  In order to 347 
eliminate such compounds, we exploited the expression of mbp as a secondary screening 348 
assay, scoring for rescue of expression around the posterior lateral line ganglion (PLLg) 349 
(Fig. 4A; Materials and Methods).  This counter screen has the advantage of assessing for 350 
up-regulation (restoration) of mbp expression in mutant embryos, in contrast to the down-351 
regulation of vcanb expression in the primary screen.  All compounds that passed the first 352 
retest for vcanb (89 compounds in total) were subjected to this secondary assay for mbp 353 
expression.  We used the same assay format and treatment time window as for vcanb, as 354 
we had previously found that treatment with IBMX between 60 and 90 hpf was also able to 355 
rescue mbp expression in adgrg6 mutants (not shown). 356 
  357 
Following two experimental repeats (n=6 fish tested per drug), compounds were categorised 358 
into groups based on their average mbp score.  These included groups of compounds that 359 
showed rescue of the mutant phenotype (an increase of mbp expression, specifically around 360 
the PLLg); no rescue (mbp expression equivalent to that in untreated adgrg6tb233c mutants), 361 
and those that resulted in a decrease in mbp expression, as shown in Figure 4A.  We 362 
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identified 41 compounds (12 from Tocris, 29 from Spectrum) that rescued mbp expression 363 
and thus represent possible modulators of Adgrg6 pathway (Fig. 4B,C; Table 1).  Twenty-364 
eight hit compounds (15 from Tocris, 13 from Spectrum) strongly could represent 365 
compounds that can rescue vcanb expression in an inner ear-specific or Adgrg6-366 
independent manner.  Alternatively, as all the assays were carried out at a single 367 
concentration (25 たM), it is possible that some or all of these compounds could rescue mbp 368 
expression at a higher concentration (as is the case for IBMX with the fr24 allele).  The 28 369 
members of this group are structurally and functionally diverse (Supplementary file 1).  370 
Finally, 22 compounds (2 from Tocris, 20 from Spectrum) reduced the expression of both 371 
vcanb and mbp.  This latter group—potential false positives in the vcanb assay—could 372 
represent general inhibitors of transcription or development, and were excluded from further 373 
analysis, resulting in a final list of 68 hit compounds (Supplementary file 1).  The heat map in 374 
Figure 5A displays these groups using data from each of the screens and retests and 375 
clusters the compounds based on their activity. 376 
  377 
Compounds that can rescue both inner ear and myelination defects  378 
The 41 compounds that could both down-regulate vcanb expression and restore mbp 379 
expression to wild-type levels in adgrg6tb233c mutants, presumed modulators of the Adgrg6 380 
signalling pathway (Table 1), are highlighted on the final combined polar scatter plot (Fig. 381 
4F).  Although hit compounds are scattered around the plot, some clustering is evident, and 382 
we chose two groups for further analysis (Fig. 4F; boxes at 300, 2500); these clusters are 383 
also clearly seen in a compound network display based on structural similarity in Fig. 5B; 384 
interactive version at 385 
https://adlvdl.github.io/visualizations/network_whitfield_vcanb_mbp/index.html).  Groups with 386 
five or more compounds included the pyridines (cluster 1, Figs 4D, 5B) and the 387 
tetranortriterpenoids (gedunin derivatives) (cluster 2, Figs 4D, 5B).  The pyridine cluster 388 
included one pyrazolopyridine and six dihydropyridines, a class of L-type calcium channel 389 
blockers with vasodilatory properties (reviewed in (Tocci et al., 2018)).  The gedunins are a 390 
family of naturally occurring compounds, previously attributed with antineoplastic and 391 
neuroprotective effects (Jang et al., 2010; Subramani et al., 2017).   392 
 393 
A selection of compounds was chosen for further study (Figs 6–8).  Two dihydropyridines, 394 
nifedipine and cilnidipine, were chosen from cluster 1.  The third compound chosen was 395 
tracazolate hydrochloride, a pyrazolopyridine derivative belonging to the 396 
nonbenzodiazepines and a known γ-aminobutyric acid A (GABAA) modulator (Thompson et 397 
al., 2002), which strongly down-regulated vcanb expression to wild-type levels.  FPL 64176 398 
was also chosen for further analysis, based on its potent efficacy in down-regulating vcanb, 399 
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and the fact that it was the only calcium channel modulator (Liu et al., 2003) that did not 400 
rescue mbp expression efficiently.  Initial experiments to repeat the rescue of the vcanb and 401 
mbp expression with freshly-sourced compounds from alternative suppliers (see Materials 402 
and Methods) confirmed that the pyridines cilnidipine, nifedipine and tracazolate 403 
hydrochloride were able to decrease otic vcanb expression and increase mbp expression 404 
around the PLLg in mutant embryos for the tb233c allele, whereas FPL 64176 was able to 405 
reduce vcanb expression but was unable to restore mbp expression to wild-type levels (Fig. 406 
6C).  407 
 408 
To examine whether the network clustering was able to predict functional activity, we 409 
selected an additional four dihydropyridines that were not represented in the Tocris or 410 
Spectrum libraries, and tested whether they could also rescue vcanb expression in 411 
adgrg6tb233c mutants.  Nilvadipine, nemadipine-A, felodipine and lercanidipine are all 412 
dihydropyridine calcium channel blockers of the type used to treat hypertension.  Nilvadipine 413 
is structurally closely related to nifedipine (Fig. 6B); as predicted, it gave a dose-responsive 414 
rescue of otic vcanb, with full rescue at 50.6 µM (Fig. 6Cvii, Fig. 7—figure supplement 1), 415 
and a strong rescue of mbp expression at 22.5 µM (Fig. 6Cxiv).  The three other compounds 416 
showed a range of efficacy in the vcanb assay at 25 た‒, with nemadipine-A showing 417 
complete rescue, felodipine mild rescue and lercanidipine no rescue (Fig. 7—figure 418 
supplement 1).  However, a higher concentration of lercanidipine (50 た‒) was able to rescue 419 
vcanb expression, whereas felodipine continued to show mild rescue at 40 µM (Fig. 7—420 
figure supplement 1).  421 
 422 
We also tested a higher concentration of a Tocris compound from the pyridine cluster, (±)-423 
Bay K 8644, which had originally scored as a non-hit in the primary screen (25 µM).  We 424 
found that this compound rescued otic vcanb expression effectively at 40 た‒, and in fact 425 
also gave a mild rescue at 25 µM in this experiment (Fig. 7—figure supplement 1).  426 
Interestingly, (±)-Bay K 8644 is a dihydropyridine that acts as a calcium channel agonist with 427 
similar activity to FPL 64176 (Hu et al., 2013; Rampe et al., 1993).  All compounds tested 428 
from cluster 1 share a large common substructure composed of a pyridine ring and its five 429 
substitutions (one phenyl ring, two ester groups, and two methyl groups).  Felodipine and 430 
nemadipine-A both have several halogen atoms bound to the phenyl ring, whereas on most 431 
of the other compounds a nitro group is bound to the phenyl ring.  The main difference 432 
between the dihydropyridine structures comes from the variety of different esters attached to 433 
the pyridine ring (Fig. 6C, Fig. 7—figure supplement 1B). 434 
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 435 
Nifedipine, cilnidipine, tracazolate hydrochloride and FPL 64176 rescue otic defects in 436 
adgrg6tb233c mutants in a dose-dependent manner  437 
The four compounds shown in Figure 6 were also selected for dose-response assessment, 438 
by exposing adgrg6tb233c embryos to concentrations ranging from 0.3 た‒ to 222.2 た‒ 439 
between 60–110 hpf.  Nine embryos were tested for each concentration, and a 1.5-fold 440 
dilution series of each drug was used.  ISH analysis of the 110-hpf embryos revealed a 441 
robust, dose-dependent down-regulation of vcanb mRNA expression in response to 442 
treatment with all four drugs (Fig. 7).  Expression of vcanb mRNA was assessed by 443 
annotating each embryo with two scores, one representing the number of unfused 444 
projections stained (Fig. 7A), and the other representing the intensity of the stain (Fig. 7B, 445 
score as in Fig. 3A).  All four drugs were able to reduce both the intensity of the ISH staining 446 
and the number of projections stained in the ear in a dose-dependent manner.  For each of 447 
the four drugs, the intensity of the vcanb staining decreased even after treatment with low 448 
doses, whereas higher doses were needed to reduce the number of the projections stained.   449 
 450 
In order to investigate whether other aspects of the ear phenotype in adgrg6tb233c mutants 451 
could be rescued by compound treatment, the inner ears of live treated embryos were 452 
observed with differential interference contrast (DIC) optics at 110 hpf (or 90 hpf in the case 453 
of FPL 64176, due to its toxicity).  Consistent with the vcanb scores for the number of 454 
projections stained, live DIC images of the inner ear revealed a dose-dependent rescue of 455 
projection fusion and pillar formation, which was greater at higher doses (Fig. 7C).  As 456 
adgrg6tb233c mutants have a swollen ear phenotype (Geng et al., 2013), measurements of the 457 
ear-to-ear width, normalised for size differences between individuals, were taken from 458 
photographs of live embryos mounted dorsally.  The results showed a dose-dependent 459 
reduction in ear swelling with increased concentration of the four drugs (Fig. 7D; Fig. 7—460 
figure supplement 2).  LD50 concentrations were also determined for each of the four 461 
compounds and ranged from 19.2 た‒ (cilnidipine) to 51.7 た‒ (tracazolate hydrochloride) 462 
(Fig. 7—figure supplement 3).   463 
 464 
Test for rescue of vcanb expression in the fr24 allele: screen for Adgrg6-specific 465 
ligands  466 
The initial screen was performed on the hypomorphic tb233c allele.  We differentiated our hit 467 
compounds further by re-screening for vcanb expression in a strong adgrg6 allele, fr24 (Fig. 468 
1B), to identify compounds that could potentially interact directly with the Adgrg6 receptor 469 
itself.  We predicted that any compounds able to rescue both alleles (such as IBMX at higher 470 
concentrations) are likely to act downstream of the receptor.  On the other hand, hits that 471 
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rescued tb233c, but were not able to rescue fr24, could potentially act as putative agonistic 472 
ligands for the Adgrg6 receptor.  Of the 41 hit compounds able to rescue both vcanb and 473 
mbp in the tb233c allele, we identified 10 compounds that also rescued vcanb expression in 474 
the fr24 screen (score sum 0–7 in Table 1, yellow), 12 compounds that gave a partial or 475 
inconclusive rescue (white), and 19 compounds that did not affect vcanb expression in the 476 
fr24 screen (score sum 9 in Table 1, grey).  The first group (yellow) are presumed to act 477 
downstream of the Adgrg6 receptor, and include colforsin, which tested positive in all assays 478 
and is a known activator of adenylyl cyclase, supporting this interpretation (Fig. 8).  The last 479 
class (grey) are of particular interest as they represent candidates for molecules that may 480 
interact directly with the receptor.  Examples of the difference in ability to rescue the two 481 
adgrg6 alleles between the two classes can be seen in Figure 8C.   482 
 483 
Interestingly, four of the 19 compounds in the last group are in the cluster of gedunin 484 
derivatives identified in Figure 4 (cluster 2), with deoxygedunin being one of the top ten most 485 
potent drugs able to rescue the tb233c allele.  The compound network shows that 38 486 
compounds with structural similarity to the gedunins are represented in the two libraries 487 
(Figs 5,8).  In the primary screens, 25/38 (66%) gedunin-related compounds affected vcanb 488 
expression to some extent (18 compounds in categories A–C and 7 in D), 9 compounds 489 
were inactive and 4 were toxic.  The majority of the gedunin-related compounds that passed 490 
both rounds of retesting were later found also to rescue mbp expression (8/10, 80%).  The 491 
shared structural characteristics of the gedunin group may give useful clues for candidate 492 
structures of agonistic ligands for Adgrg6.  In summary, our study demonstrates a novel 493 
screening approach which, when combined with chemoinformatics analysis, is able to 494 
delineate both expected downstream rescuers of the Adgrg6 pathway and several 495 
candidates for drugs that may interact directly with the Adgrg6 receptor.  496 
  497 
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DISCUSSION 498 
Adhesion GPCRs are critical regulators of development and disease, driving cell-cell and 499 
cell-ECM communications to elicit internal responses to extrinsic cues.  This study set out to 500 
identify positive modulators of the Adgrg6 signalling pathway, a key regulator of myelination 501 
and inner ear development in the zebrafish embryo.  Use of a whole-animal phenotypic 502 
(mutant rescue) screen gave the potential to identify compounds affecting the entire Adgrg6 503 
pathway in the correct cellular context.  We have used a simple in situ hybridisation 504 
approach to assay vcanb expression in the inner ear of adgrg6 mutants, exploiting an easily 505 
identifiable phenotype that could be scored manually.  Following our primary screen of 3120 506 
small molecules, we tested 89 hit compounds in a counter screen for rescue of the 507 
myelination defect in adgrg6 mutant embryos.  We identified 41 compounds that can both 508 
rescue vcanb expression in the inner ear and mbp expression in Schwann cells of adgrg6 509 
hypomorphic mutants, suggesting these are Adgrg6 pathway-specific modulators.  Further 510 
analysis of a strong adgrg6 allele, fr24, identified a subset of 19 compounds that are 511 
potential direct interactors of the Adgrg6 receptor.  This analysis, combined with 512 
chemoinformatics analysis of the identified hit compounds, has identified clusters of 513 
compounds acting at different levels of the Adgrg6 pathway.   514 
 515 
An optimal drug screening assay design identifies the maximum number of hit compounds 516 
with the minimum number of false positives and false negatives.  Chemical screening 517 
assays using zebrafish range from simple morphology screens (Yu et al., 2008) through to 518 
high-tech, automated methods for quantitative image analysis (Early et al., 2018) or 519 
behavioural analysis (Bruni et al., 2016; Rennekamp et al., 2016) (reviewed in (Kalueff et al., 520 
2016)).  We used an in situ hybridisation screen to analyse gene expression changes, as 521 
this has the advantages of being scalable to different sized projects and relatively 522 
inexpensive to perform—with results that are stable and reproducible.  Spatial resolution of 523 
staining patterns can be accurately scored: expression pattern screens have recently been 524 
used to identify small molecules that can induce subtle differences in gene expression 525 
domains along the pronephros (Poureetezadi et al., 2016) and in the somites (Richter et al., 526 
2017).  Although quantification of gene expression levels is less reliable with an enzymatic 527 
reaction compared with a fluorescent signal, we utilised the strong contrast between the high 528 
vcanb expression in the ear of adgrg6 mutant fish compared with the low expression in a 529 
small dorsal region of the wild-type ear at 4 dpf to produce a robust scoring system for our 530 
phenotype rescue.  531 
 532 
Relatively few zebrafish screens have been undertaken to identify compounds that can 533 
increase myelination (Buckley et al., 2010; Early et al., 2018) or restore myelination in 534 
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neuropathy models (Zada et al., 2016), which is in part due to the complex distribution of 535 
glial cells in both the CNS and PNS.  Performing the primary screen using our ear marker, 536 
vcanb, enabled us to bypass the difficulties of scoring and quantification of mbp staining on 537 
a large scale; instead, mbp expression was used as a counter screen on a limited number of 538 
cherry-picked hits.  Contrary to the primary assays, which screened for down-regulation of 539 
vcanb expression, the counter screen assayed for up-regulation of mbp expression, enabling 540 
the identification of 21 false-positive compounds that down-regulate the expression of both 541 
genes (presumably by inhibiting transcription).  542 
 543 
Determining the false-negative rate for any screen is difficult.  In our assay we used only one 544 
concentration of compound (25 µM), so it is likely that some of the compounds that were 545 
toxic or showed no effect at 25 µM—and thus eliminated from our screen—would be 546 
effective at lower or higher concentrations, respectively.  One possibility would be to run a 547 
parallel screen at a lower or higher concentration or use an alternative protocol with shorter 548 
incubation times, an approach that has recently proved successful at identifying different 549 
compounds influencing segmentation in zebrafish (Richter et al., 2017).  Here, the 550 
compounds were found to be most active in the range of 10–50 µM, supporting our choice of 551 
25 µM for the primary screen.  However, increasing the number of replicates with different 552 
drug concentrations or assay conditions has significant implications on the cost and time 553 
taken to complete the screen, reducing the number of compounds analysed and the 554 
potential hits identified.  An alternative method is to use a structural network to select and 555 
prioritise candidate compounds that have a similar structure to hit compounds and test these 556 
at different concentrations. Using this approach, we identified (±)-Bay K 8644 as an 557 
additional hit from the pyridine cluster when tested at a higher concentration.  Our minimum 558 
estimate for the false-negative rate is 5%, based on the seven compounds (out of a total of 559 
155) that were duplicated in both libraries and had a significantly different score after 560 
retesting, being classified as a hit in one library but not in the other.  It is possible that this is 561 
due to differences in chemical purity from the different suppliers.  Other false-negative 562 
compounds could include those that are unable to penetrate into the ear.  Neomycin, for 563 
example, is toxic to the superficial hair cells of the lateral line system, but is ineffective on 564 
inner ear hair cells unless microinjected into the ear (Buck et al., 2012).  Other compounds 565 
that we will have missed could include myelination-specific compounds, as the primary 566 
assay scored for the ear phenotype only.  Given that several compounds were positive hits 567 
for the rescue of vcanb in the ear and negative for mbp, it is likely that tissue-specific 568 
functions of Adgrg6 are mediated through different downstream pathways or are stimulated 569 
by different ligands.  570 
 571 
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Our positive control compound, IBMX, was identified independently through our screen as a 572 
category A hit.  The hit compound colforsin was found to be more potent and less toxic than 573 
the related control compound forskolin, and had the highest score in every assay, showing 574 
full rescue of the strong fr24 allele.  Both these observations highlight the robustness of the 575 
assay and the consistency of the scoring process.  In total, the final number of hit 576 
compounds identified was similar in both the compound libraries screened, with 42 577 
compounds identified from the Spectrum library (2.1%) and 27 compounds from the Tocris 578 
library (2.4%).  These hit rates are comparable to those found in other similar screens 579 
(Baxendale et al., 2012; Vettori et al., 2017; Wiley et al., 2017).   580 
 581 
Chemoinformatics analysis and visualisation of the results provided additional context to the 582 
identified hit compounds.  The polar scatter plot displayed an initial overview of the results 583 
and allowed the identification of six different structurally-related clusters of active 584 
compounds with similar structure.  The compound network focused the analysis on highly 585 
detailed similarity relationships inside each compound cluster, yielding a wealth of structure-586 
activity relationship information that could prove very useful for any future optimisation of the 587 
identified hit compounds.  Seven of the 41 hit compounds that rescued vcanb and mbp 588 
expression are Ca2+-channel modulators.  Six of these (nifedipine, cilnidipine, nitrendipine, 589 
nimodipine, efonidipine, niguldipine) belong to the chemical group of dihydropyridines 590 
(cluster 1), and initial investigations into compounds with similar structures identified four 591 
additional compounds in this class.  Several dihydropyridines are known to have 592 
neuroprotective effects in mammalian models.  Nimodipine, for example, has been shown to 593 
trigger remyelination in a mouse model of multiple sclerosis and to improve repair in 594 
peripheral nerve crush injuries in rats (Schampel et al., 2017; Tang et al., 2015), and some 595 
compounds have shown promise at clearing toxic proteins in animal models of 596 
neurodegeneration, including felodipine (Siddiqi et al., 2019) and nilvadipine (Paris et al., 597 
2011).  As dihydropyridines have been reported to inhibit cAMP phosphodiesterases 598 
(Sharma et al., 1997), protection of cAMP from degradation might be another mechanism 599 
whereby these molecules exert their ameliorating action on the adgrg6 mutant phenotype. 600 
 601 
Phenotypic screens are advantageous for assessing models of multifactorial pathological 602 
conditions, such as hereditary neuropathies and cancer (reviewed in (Baxendale et al., 603 
2017)).  However, one of the challenges for phenotypic screening is the identification of the 604 
specific target for any hit compound, as multiple pathways and different cell types can 605 
contribute to a positive read-out in the screening assay.  Our aim was to identify compounds 606 
that could potentially interact directly with the Adgrg6 receptor.  We were able to separate hit 607 
compounds into different groups based on their ability to rescue otic phenotypes caused by 608 
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missense (tb233c) and nonsense (fr24) mutations.  In total, we found 19 hits that could 609 
rescue vcanb expression and mbp expression in the tb233c allele, but were unable to 610 
rescue the fr24 allele.  We hypothesise that the fr24 allele is unable to produce the full-611 
length Adgrg6 protein including the CTF, and therefore any compounds that interact directly 612 
with the receptor would not be able to rescue any CTF-dependent function in this strong 613 
allele.  Further analysis will be needed to determine whether any of these compounds can 614 
bind directly to the Adgrg6 receptor, for example by assessing stimulation of cAMP and 615 
direct binding in in vitro assays.  However, this approach of using a combination of null and 616 
hypomorphic alleles in zebrafish whole-organism screening with the aim of identifying target-617 
specific compounds is particularly exciting and one that the advent of CRISPR/Cas9 618 
technology is placed to take full advantage of, since it is now possible to generate designer 619 
mutations in the zebrafish through homology-directed repair (Hruscha et al., 2013; Hwang et 620 
al., 2013; Komor et al., 2016). 621 
 622 
It is of interest to note that one of the main groups of compounds identified as potential 623 
interactors of the receptor in the fr24 screen is a cluster of gedunin derivatives (cluster 2).  624 
One of these compounds, deoxygedunin, has previously been identified as a TrkB agonist 625 
that has neuroprotective properties (Nie et al., 2015), can promote axon regeneration after 626 
nerve injury (English et al., 2013), and, interestingly, has been found to protect the vestibular 627 
ganglion from degeneration in mice mutant for BDNF (Jang et al., 2010).  More recently, 628 
gedunin derivatives, including 3-α-DOG, have been shown to act as partial agonists for the 629 
closely related aGPCR, ADGRG1 (formerly GPR56) (Stoveken et al., 2018), a key regulator 630 
of myelination in both the CNS and PNS (Ackerman et al., 2015; Ackerman et al., 2018; 631 
Giera et al., 2015; Salzman et al., 2016).  While further work will be necessary to determine 632 
if gedunin-type molecules can also bind and activate zebrafish Adgrg6 by interacting directly, 633 
these studies set a precedent for this type of interaction.   634 
 635 
GPCRs can be modulated by the membrane lipid cholesterol, where interactions with the 636 
7TM domain can provide plasticity for the receptors by altering their stability and structure 637 
(Huang et al., 2018; Prasanna et al., 2016).  In addition, cholesterol can activate the 638 
hedgehog signalling pathway directly by binding to the extracellular domain of the GPCR 639 
Smoothened (Huang et al., 2018; Luchetti et al., 2018).  Although cholesterol was not 640 
identified as a hit in our primary screen, we did identify two cholesterol-lowering drugs, 641 
ezetimibe (Altmann et al., 2004) and rosuvastatin (Istvan and Deisenhofer, 2001), as 642 
putative modulators of the Adgrg6 pathway.  Whether these act by altering the activity of 643 
Adgrg6 through altering cholesterol levels remains to be determined. 644 
 645 
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In addition to the dihydropyridines (cluster 1) and the tetranortriterpenoid (gedunin-derived) 646 
compounds (cluster 2), there are also clusters of steroid hormones (danazol, 647 
hydroxyprogesterone, pregnenalone succinate, hydrocortisone hemisuccinate) and flavonoid 648 
compounds (baicalein, tangeritin, nobiletin, dimethylnobiletin, hexamethylquercetagetin).  649 
The flavonoids are a group of molecules with wide ranging activities, including anti-cancer 650 
(Ma et al., 2015) and neuroprotective properties (reviewed in (Braidy et al., 2017)).  All four 651 
O-methylated flavonoids that rescued vcanb and mbp expression in tb233c mutants were 652 
also able to rescue fr24 allele in our assay, suggesting that they act downstream of the 653 
Adgrg6 receptor.  654 
 655 
Our screen identified 28 compounds that down-regulated vcanb expression, but did not 656 
rescue mbp expression, which may provide useful tools to manipulate semicircular canal 657 
formation in vivo.  Versican and other chondroitin sulphate proteoglycans (CSPGs) are 658 
associated with a number of human pathologies; Versican overexpression has been shown 659 
to be strongly involved in inflammation, cancer progression and the development of lung 660 
disorders (reviewed in (Andersson-Sjöland et al., 2015; Ricciardelli et al., 2009; Wight et al., 661 
2017)).  CSPGs and hyaluronan are components of the inhibitory scar that forms at the site 662 
of injury after CNS damage, preventing axon regeneration (Silver and Miller, 2004).  In 663 
addition, CSPGs have been shown to inhibit the ability of oligodendrocytes to remyelinate 664 
axons, a process that is reversed by reduction of CSPG levels (Keough et al., 2016; 665 
Pendleton et al., 2013).  Whether the down-regulation of CSPGs to promote remyelination 666 
occurs via a similar mechanism to that involved in Adgrg6-regulated projection fusion 667 
remains to be determined.  However, it is of interest that a key regulator of myelination, 668 
Adgrg1, has also been recently shown to reduce fibronectin deposition and inhibit cell-ECM 669 
signalling to prevent metastatic melanoma growth (Millar et al., 2018).  670 
 671 
In conclusion, our data show that vcanb expression in the adgrg6tb233c mutant ear provides a 672 
robust, easy-to-use screening tool to identify drugs that target the Adgrg6 pathway.  In 673 
combination with the different alleles available for adgrg6 in zebrafish, this in vivo platform 674 
provides an excellent opportunity to find hit compounds that may be specific for Adgrg6 in 675 
counter screens.  These may provide a starting point for the development of therapeutic 676 
approaches towards human diseases where ADGRG6 or myelination is affected.  We have 677 
identified groups of structurally-related compounds that can rescue adgrg6 mutant defects, 678 
including those that are likely to act downstream of the Adgrg6 pathway, and others that are 679 
candidates for interacting with the Adgrg6 receptor.  The chemical analysis and structural 680 
comparison of the compounds shown to be putative Adgrg6 receptor agonists will contribute 681 
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to the elucidation of the physical properties responsible for ligand binding and will provide 682 
further insight on the underlying mechanism of Adgrg6 signalling.   683 
 684 
  685 
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MATERIALS AND METHODS 686 
Animals  687 
Standard zebrafish husbandry methods were employed (Westerfield, 2000).  To facilitate 688 
visualisation of in situ hybridisation (ISH) staining patterns, embryos of the nacre (mitfaw2/w2) 689 
strain (ZDB-GENO-990423-18), which lack melanophores (Lister et al., 1999), but are 690 
phenotypically wild-type for expression of vcanb and mbp, were used as controls for all drug 691 
screening experiments.  The wild-type strain used for dose-response experiments was 692 
London Wild Type (LWT).  adgrg6 mutant alleles used were lautb233c (formerly bgetb233c) and 693 
laufr24 (ZDB-GENE-070117-2161) (Geng et al., 2013; Whitfield et al., 1996), and were raised 694 
on a pigmented background.  In all cases shown, mutant embryos are homozygous for the 695 
respective allele.  The transgenic strain used for imaging in Fig. 1 and in the videos was 696 
Tg(smad6b:GFP), a gift of Robert Knight (Baxendale and Whitfield, 2016).  Prior to 697 
treatment, embryos were raised in E3 embryo medium (Westerfield, 2000) at 28.5°C.  We 698 
have used the term embryo throughout to refer to zebrafish embryos and larvae from 0–5 699 
days post fertilisation (dpf). 700 
 701 
Compound storage, aliquoting and administration to embryos  702 
Chemical compounds from the Tocriscreen Total library (Tocris, Batch #2884, 1120 703 
compounds) and The Spectrum Collection (Microsource Discovery Systems, Batch 704 
#100122, 2000 compounds) were arrayed in MultiScreen-Mesh 96-well culture receiver trays 705 
(Millipore) in columns 2–11 and diluted to 25 たM in E3 medium for drug screening.  Control 706 
wells contained either IBMX (3-isobutyl-1-methylxanthine, Sigma, 50 たM and 100 たM), 707 
DMSO (Sigma, 1% in E3) or E3, in columns 1 and 12 (see diagram of the plate layout in Fig. 708 
2).  Wild-type (LWT and nacre) and homozygous adgrg6tb233c mutant embryos were raised to 709 
50 hpf at 28.5°C in E3 medium, dechorionated manually with forceps, and then incubated at 710 
20°C overnight to slow down development and facilitate timing of experimental treatments.  711 
This regime reduced ear swelling, but did not reduce otic vcanb levels, in mutant embryos.  712 
Embryos at the 60 hpf stage were aliquoted at three embryos per well into MultiScreen-713 
Mesh mesh-bottomed plates (Millipore) and transferred to the drug plate (receiver tray; see 714 
above).  Assay plates were incubated at 28.5°C for 28 hours and the embryos were then 715 
transferred to 4% paraformaldehyde and stored at 4°C overnight.  Embryos were bleached 716 
according to the standard protocol (Thisse and Thisse, 2008) and stored at -20°C in 100% 717 
methanol until required for ISH.  Hits identified in the primary screen were rescreened using 718 
the same protocol.  Selected compounds were purchased separately from Sigma (nifedipine, 719 
cilnidipine, nilvadipine), Sigma LOPAC Collection (nemadipine-A, felodipine, lercanidipine), 720 
Cayman Chemicals (FPL 64176) and Santa Cruz Biotechnology (tracazolate hydrochloride).   721 
 722 
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Whole-mount in situ hybridisation analysis of gene expression 723 
Digoxigenin-labelled RNA probes for vcanb (Kang et al., 2004) and mbp (mbpa) (Brösamle 724 
and Halpern, 2002) were prepared as recommended (Roche).  Whole-mount ISH was 725 
performed using standard procedures (Thisse and Thisse, 2008), modified for the Biolane 726 
HTI 16V in situ robot (Intavis) and MultiScreen-Mesh mesh-bottomed plates to increase 727 
throughput (Baxendale et al., 2012).  Stained embryos were scored manually by at least two 728 
people and any discrepancies between the results were re-analysed. For the dose-response 729 
data the results were blinded and re-scored to check for consistency. 730 
 731 
Scoring systems for vcanb and mbp expression 732 
To score the efficacy of the drugs in down-regulating vcanb mRNA levels, a scoring system 733 
from 0 to 3 was used, with 0 being the score for a very efficient drug (a ‘hit’) that can 734 
suppress vcanb expression back to almost wild-type levels, and 3 the score for a drug that 735 
did not have any effect on vcanb mRNA levels expressed in the adgrg6 mutant ear.  Scores 736 
1 and 2 were given to drugs that showed an ability to down-regulate vcanb expression to 737 
some extent, with 1 given for a stronger down-regulation than 2 (Figure 3A).  Drugs were 738 
then classified into categories A–E, according to the combined score from the three embryos 739 
treated with each drug (Figure 3B).   740 
 741 
For the mbp counter screen (Fig. 4A,B), a score of 3 was used for embryos where mbp 742 
mRNA expression was rescued to wild-type levels, a score of 2 for embryos that showed 743 
some mbp expression around the PLLg (weaker than wild-type levels) and a score of 1 in 744 
cases where the mbp expression was identical to the one seen in untreated adgrg6tb233c 745 
mutants (i.e. lacking mbp expression around the PLLg).  The fact that mbp expression is not 746 
missing altogether from other areas of the PNS in adgrg6tb233c mutants allowed us to use a 747 
score of 0 in cases where mbp expression levels were lower than those typically seen in 748 
adgrg6tb233c mutants.   749 
 750 
Hit selection 751 
Drugs categorised as A or B were considered successful and were cherry-picked into new 752 
drug assay plates for further testing.  Drugs categorised as C were potentially interesting 753 
and a few were used to complete a 96-well cherry-pick plate (37/96 compounds). Drugs 754 
categorised as D and E were considered to show incomplete or no inhibition of vcanb 755 
expression, respectively.  Drugs from category F caused severe developmental 756 
abnormalities, heart oedema, brain oedema or death at the end of the treatment and 757 
therefore were characterised as toxic.  Category G represented drugs that were potentially 758 
corrosive, as no fish were found in these wells at the end of the treatment, although this 759 
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could also have resulted from death of the embryos followed by digestion by 760 
microorganisms, or through experimental error.  Drugs that fell into any of the categories D–761 
G and most from category C (59) were eliminated from the assay and were not followed 762 
further.  In addition, 10 compounds from category A and B were unable to be tested further 763 
due to compound availability issues. 764 
 765 
Compounds taken forward for secondary assays were chosen by two criteria:  1.  A final 766 
average score for three replicates (total 9 embryos) with a category A–C;  2.  No individual 767 
score >7.  In total, 91 compounds were picked for the counter screen, including two that 768 
were present in both libraries, resulting in 89 individual compounds.  The screening pipeline 769 
is shown in Figure 4G and the subsequent grouping of compounds is described in Figures 770 
4,5,6,8. 771 
 772 
Dose-response and LD50 assays 773 
Selected compounds were tested in dose-response assays.  In order to assess the ear 774 
swelling in drug-treated adgrg6tb233c mutant embryos, the ear-to-ear width was measured 775 
from photographs of live embryos mounted dorsally, and normalised for the size of the head, 776 
using CELLB software (for details, see Fig. 7—Figure supplement 2).   777 
 778 
An LD50 curve was plotted for the adjusted exposure time (60–110 hpf), using 16 LWT wild-779 
type embryos (biological replicates) per concentration.  To avoid cross-contamination from 780 
dead embryos, each wild-type (LWT) embryo was kept in a separate well of a 96-well plate.  781 
At the end of each treatment, the number of dead embryos (no heartbeat for 10 seconds) 782 
was recorded. 783 
  784 
Microscopy and photography  785 
Still images of live embryos were taken using an Olympus BX51 microscope, C3030ZOOM 786 
camera and CELLB software, and assembled with Adobe Photoshop.  All micrographs are 787 
lateral views with anterior towards the left and dorsal towards the top, unless otherwise 788 
stated.  For archiving, fixed and stained embryos were imaged in MultiScreen-Mesh plates 789 
containing 50% glycerol, using a Nikon AZ100 microscope with an automated stage (Prior 790 
Scientific).  A compressed in-focus image was generated using the NIS-Elements Extended 791 
Depth of Focus software (Nikon). 792 
 793 
Time-lapse imaging of live embryos was performed on a Zeiss Z.1 light-sheet microscope. 794 
adgrg6fr24 homozygous mutant embryos in a Tg(smad6b:GFP) background were mounted at 795 
60 hpf in 0.7% agarose with anaesthetic (MS-222; 160 µg/ml) and 0.003% PTU (to prevent 796 
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pigment formation).  Images were taken of a dorsal view of the ear every 5 minutes (200 z-797 
slices, 1 µm sections).  A control time-lapse of a wild-type sibling embryo (images taken at 798 
10-minute intervals) was taken on a separate day.  Images were cropped and a subset of z-799 
slices through the anterior (adgrg6fr24) and posterior (phenotypically wild-type sibling) 800 
projections were used to make Maximum Intensity Projection videos of projection fusion in 801 
the wild-type sibling and the swollen projections in adgrg6fr24 mutant embryo.  The two 802 
videos do not correspond exactly to the same developmental stage. 803 
 804 
Chemoinformatics analysis and data visualisation 805 
Chemical structures of the library compounds represented as SMILES (Weininger, 1988) 806 
were obtained from vendor catalogues.  Molecules were standardised using the wash 807 
procedure of MOE (Chemical Computing Group Inc., Molecular Operating Environment 808 
(MOE), Montréal, QC, 2011), accessed through KNIME (Berthold et al., 2009).  809 
Standardised molecules were analysed using RDKit (RDKit: Open-Source Cheminformatics, 810 
http://www.rdkit.org/, accessed 06 Nov. 2018) in Python (Python Software Foundation: 811 
Python language reference, version 3, https://www.python.org/, accessed 06 Nov. 2018).  812 
Morgan fingerprints of radius 2 (equivalent to ECFP4 (Rogers and Hahn, 2010)) were 813 
computed for each compound.  Compound similarity was calculated using the Tanimoto 814 
coefficient (Willett et al., 1998) of the fingerprints using the scikit-learn library (Pedregosa et 815 
al., 2011).  Based on the similarity matrix between all compound pairs, a dendrogram was 816 
obtained using the SciPy library (SciPy: Open Source Scientific Tools for Python, 817 
http://www.scipy.org/, accessed 06 Nov. 2018).  The polar scatterplot was created using the 818 
matplotlib library (printed version) (Hunter, 2007) and plotly (interactive version) (Plotly 819 
Technologies Inc, Collaborative data science, Plotly, Montréal, QC, 2015.).  To identify 820 
duplicated molecules, the InChIKey (Heller et al., 2015) was computed for each compound 821 
and all pairs of compounds were checked for identical InChIKeys.  To create the compound 822 
network, the similarity matrix computed for the dendrogram was transformed into an 823 
adjacency matrix using a threshold value of 0.5, i.e. compounds with a similarity value over 824 
0.5 are connected with an edge.  The network visualisation was created using Cytoscape 825 
(Shannon et al., 2003). 826 
 827 
Statistical analysis 828 
Statistical analyses were performed using GraphPad Prism version 7 for Mac, GraphPad 829 
Software, La Jolla California USA, www.graphpad.com.  The Strictly Standardised Mean 830 
Difference (SSMD, β) (Zhang, 2007) for the dose-response measurements in Fig. 7D was 831 
calculated using the formula: 832 
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Tables and Figures 858 
 859 
Table 1.  List of the 41 hit compounds that rescued the expression of both vcanb and mbp in 860 
adgrg6
tb233c mutants, thus representing putative Adgrg6 pathway modulators 861 
The table includes the plate and well ID, along with known activities and the average score from nine 862 
adgrg6
tb233c embryos in the vcanb assay, from six adgrg6tb233c embryos in the mbp assay and from 863 
three adgrg6fr24 embryos in the fr24 assay.  Grey shading indicates compounds presumed to interact 864 
with Adgrg6 receptor directly, while yellow shading indicates compounds presumed to be downstream 865 
effectors of the pathway.  Abbreviations: DE, dead embryos; ND, no data; S, Spectrum; T, Tocris.  866 
*Note that cilnidipine can rescue fr24 at 40 µM (data not shown). 867 
 868 
Table 1—source data 1 869 
  870 
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 871 





1 S18 C09 CARAPIN-8(9)-ENE undetermined  0.00 8.50 9.00 
2 S25 D08 3-ISOBUTYL-1-METHYLXANTHINE (IBMX) 
phosphodiesterase inhibitor, non-selective 
adenosine receptor antagonist 2.00 8.50 9.00 
3 S17 F05 DEOXYGEDUNIN neuroprotective 2.00 8.00 9.00 
4 S23 F10 DIHYDROFISSINOLIDE undetermined 2.67 7.50 9.00 
5 S04 B02 IVERMECTIN antiparasitic 2.33 7.00 9.00 
6 T01 F06 SC-10 protein kinase C activator, NMDA receptor activator 5.67 6.50 9.00 
7 T01 H11 1,3-DIPROPYL-8-PHENYLXANTHINE  Selective adenosine A1 receptor antagonist 3.33 6.50 9.00 
8 S17 E02 3-DEOXO-3BETA-ACETOXYDEOXYDIHYDROGEDUNIN undetermined  0.00 6.50 9.00 
9 T11 F07 CILNIDIPINE* dihydropyridine N- and L-type Ca
2+ channel 
blocker  2.00 6.50 9.00 
10 S13 F03 AMIODARONE HYDROCHLORIDE  coronary vasodilator, Ca2+ channel blocker 5.00 6.50 9.00 
11 S06 E02 HYDROCORTISONE HEMISUCCINATE glucocorticoid 3.67 6.00 9.00 
12 T01 C04 (RS)-(TETRAZOL-5-YL)GLYCINE highly potent NMDA receptor agonist 3.00 5.00 9.00 
13 S02 E05 LOMEFLOXACIN HYDROCHLORIDE antibacterial 5.33 5.00 9.00 
14 S13 E04 ETHAMIVAN CNS & respiratory stimulant 4.67 5.00 9.00 
15 T08 B04 CGS 15943 potent adenosine receptor antagonist 5.33 4.50 9.00 
16 S13 E09 ASTEMIZOLE H1 antihistamine (nonsedating) 4.67 4.50 9.00 
17 T02 A09 SKF 91488 DIHYDROCHLORIDE histamine N-methyltransferase inhibitor 3.00 4.00 9.00 
18 S25 F05 11ALPHA-HYDROXYPROGESTERONE HEMISUCCINATE glucocorticoid 2.67 4.00 9.00 
19 T14 A07 EFONIDIPINE HYDROCHLORIDE MONOETHANOLATE 
dihydropyridine L-type and T-type 
Ca2+ channel blocker  3.67 4.00 9.00 
20 T05 C09 NIFEDIPINE dihydropyridine L-type Ca2+ channel blocker  4.33 7.00 8.00 
21 T05 E08 CGP 37157 antagonist of mitochondrial Na
+/Ca2+ 
exchange 3.67 6.50 8.00 
22 S05 D03 DANAZOL anterior pituitary suppressant, anti-estrogenic  1.00 5.00 8.00 
23 S18 H09 XANTHYLETIN undetermined 1.00 4.50 8.00 
24 S18 A06 FERULIC ACID antineoplastic, choleretic, food preservative 3.67 4.00 8.00 
25 S18 F02 ALPHA-DIHYDROGEDUNOL undetermined 2.33 4.00 8.00 
26 T05 F04 (S)-(+)-NIGULDIPINE HYDROCHLORIDE 
dihydropyridine L-type Ca2+ channel blocker, 
g1 antagonist 3.67 5.00 7.00 
27 T07 F02 TRACAZOLATE HYDROCHLORIDE subtype-selective GABAA allosteric modulator 2.33 4.50 7.00 
28 S10 E02 NIMODIPINE dihydropyridine L-type Ca2+ channel blocker  0.33 7.00 6.00 
29 S17 E06 3BETA-ACETOXYDEOXODIHYDROGEDUNIN undetermined 2.00 4.50 5.00 
30 S17 F02 DIHYDROGEDUNIN undetermined 1.67 5.00 2.00 
31 S22 F09 TANGERITIN undetermined 1.33 5.50 1.00 
32 S10 F07 COLFORSIN adenylate cyclase activator, antiglaucoma, hypotensive, vasodilator  0.00 9.00 0.00 
33 T04 G02 IMILOXAN HYDROCHLORIDE selective g2B-adrenoceptor antagonist. 0.67 9.00 ND 
34 S24 C03 3ALPHA-ACETOXYDIHYDRODEOXYGEDUNIN undetermined 0.33 8.50 DE 
35 S11 E02 EZETIMIBE antihyperlipidemic (sterol absorption inhibitor) 2.00 7.50 0.00 
36 S10 E06 NITRENDIPINE dihydropyridine L-type Ca2+ channel blocker  1.33 7.00 ND 
37 S11 E08 ROSUVASTATIN CALCIUM antihyperlipidemic 0.00 6.00 0.00 
38 S22 C07 DEMETHYLNOBILETIN undetermined 0.00 6.00 0.00 
39 S22 G11 HEXAMETHYLQUERCETAGETIN undetermined 0.00 5.50 DE 
40 S22 F08 NOBILETIN matrix metaloproteinase inhibitor, antineoplastic, anti-ERK, NF-せB suppressor 0.00 5.00 DE 
41 S12 H07 PREGNENOLONE SUCCINATE glucocortcoid, antiinflammatory 4.67 4.00 DE 
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 874 
Figure 1.  Comparison of adgrg6 mutant allele phenotypes in the inner ear and peripheral 875 
nervous system 876 
A.  (i–iii)  Live images of 4 dpf otic vesicles, lateral view.  (i) wild-type sibling, (ii) adgrg6tb233c, (iii) 877 
adgrg6
fr24 showing the swollen, unfused projections in the mutant otic vesicles in ii and iii compared 878 
with the fused pillars in the wild-type ear.  (iv–vi) ISH with vcanb at 4 dpf.  (iv) Wild-type sibling, (v) 879 
adgrg6
tb233c, (vi) adgrg6fr24 mutant ears showing overexpression of vcanb in the unfused projections.  880 
Stronger staining is seen in the stronger allele, fr24.  (vii–xi) ISH with mbp at 4dpf, (vii-ix) dorsal 881 
views, (x–xii) lateral views.  (vii, x) wild-type sibling, (viii, xi) adgrg6tb233c, (ix, xii) adgrg6fr24 showing 882 
complex staining patterns in the PNS (black arrows and arrowheads) and CNS (white arrowheads).  883 
mbp staining around the PLLg is absent in both tb233c and fr24 alleles (black arrowheads); staining in 884 
the posterior lateral line nerve is variable in tb233c mutants and absent in fr24 mutants (black arrows).  885 
B. Schematic diagram showing the structure of the Adgrg6 receptor and the positions of the predicted 886 
amino acid changes for the two adgrg6 mutant alleles used in this study.  C.  Light-sheet microscope 887 
images using a Tg(smad6b:GFP) line, showing a dorsal view of the ear (anterior to the top).  (i–iii) 888 
Wild-type sibling showing anterior and posterior pillars formed from fused projections (iii).  Note that 889 
images are flipped horizontally from the originals for ease of comparison (see Video 1; t0 on the stills 890 
corresponds to ~100 mins into the video).  (iv–vi) still images from a time-lapse video of adgrg6fr24 891 
mutant with unfused projections that rotate around each other (see Video 2).  Abbreviations: AC, 892 
lumen of anterior semicircular canal; ap, anterior projection; CTF, carboxy-terminal fragment; CUB, 893 
Complement C1r/C1s, Uegf, BMP1 domain; ECD, extracellular domain; GAIN, GPCR auto-proteolysis 894 
domain; GPS, GPCR proteolytic site; HBD, hormone binding domain; ICD, intracellular domain; NTF, 895 
amino-terminal fragment; PC, lumen of posterior semicircular canal; pp, posterior projection; PTX, 896 
Pentraxin domain; vp, ventral projection; 7TM, 7-transmembrane domain.  Scale bars: 50 たm in Ai, for 897 
Aii–vi; 100 たm in Avii, for Aviii–xii; 20 たm in Ci, for Cii–vi. 898 
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Video 1 900 
Light-sheet microscope time-lapse video using the Tg(smad6b:GFP) line, which marks cell 901 
membranes of the otic epithelium.  Dorsal view (anterior to top) of the left inner ear of a phenotypically 902 
wild-type sibling embryo showing the anterior, lateral and posterior projections (the anterior projection 903 
is partially out of view).  In the video, the posterior projection grows and meets the posterior bulge 904 
from the lateral projection.  The projection and bulge meet, fuse and resolve to form a pillar over 900 905 
minutes (approximately 55 hpf–70 hpf).  The video shows a Maximum Intensity Projection of selected 906 
z-slices spanning approximately 6 µm, captured every 10 minutes, and played back at 10 frames per 907 
second.  Selected stills from the video, flipped horizontally to match the panels showing the mutant 908 
ear, are shown in Fig. 1C. 909 
Video 2 910 
Light-sheet microscope time-lapse video using the Tg(smad6b:GFP) line.  Dorsal view of the right 911 
inner ear of an adgrg6fr24 mutant embryo showing anterior, lateral and posterior projections (the 912 
posterior projection is partially out of view).  In the video, the anterior projection and anterior bulge 913 
from the lateral projection touch, but continue to grow past one another.  The unfused projections 914 
rotate around each other over 900 minutes (approximately 60 hpf–75 hpf).  The video shows a 915 
Maximum Intensity Projection of selected z-slices spanning approximately 20 µm, captured every 5 916 
minutes, and played back at 20 frames per second.  Selected stills from the video are shown in Fig. 917 
1C. 918 




Figure 1—figure supplement 1.  Quantification of mbp expression around the posterior lateral 922 
line ganglion in adgrg6tb233c mutants and wild-type sibling embryos  923 
A.  Top, wild-type (WT) sibling: bright-field image of 5 dpf embryo stained with mbp. Dorsal view, 924 
anterior to the left.  Blue box indicates the region of interest (ROI) used for the quantification of the left 925 
and right posterior lateral line ganglion region. Below, three sets of images of the left and right ROI for 926 
each of 10 embryos (total of 20 areas), including the bright-field images, the threshold area (red) 927 
levels set with HSB on Fiji (Hue:166–236, Saturation:43–98, Brightness:31–184), and the binary 928 
image used to determine the area of staining.  B.  adgrg6tb233c mutant embryo images comparable to 929 
those shown in A with identical threshold settings used in Fiji.  C.  Comparison of the area of mbp 930 
staining between the adgrg6tb233c mutant and wild-type sibling embryos using the quantification 931 
obtained in A and B.  ****p<0.0001, Student’s t-test.  Error bars represent the mean ± 95% CI.    932 
Figure 1—figure supplement 1—source data 1 933 





Figure 2. Overview of the screening assay protocol and strategy 938 
A.  Schematic of the screening assay protocol.  Homozygous adult adgrg6tb233c mutant fish were 939 
paired to raise large numbers of adgrg6tb233c mutant embryos.  Embryos were grown until 60 hpf, 940 
when the lateral, anterior and posterior epithelial projections in the inner ear are evident.  Three 941 
embryos were aliquoted into each well of a mesh-bottomed multiwell plate in E3 medium.  The mesh-942 
bottomed plate was then transferred to the drug plate containing control compounds as shown in the 943 
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plate layout and library compounds at 25 µM in 250 µL of E3 embryo medium.  Plates were incubated 944 
at 28°C until 90 hpf.  The mesh-bottomed plate and embryos were then transferred to 4% PFA for 945 
fixation (4°C, overnight) and then processed for ISH to vcanb.  Micrographs show a selection of 946 
typical results.  Treatment with 100 µM IBMX (positive control, top) results in loss (rescue) of otic 947 
vcanb expression (white arrowhead).  Strong otic vcanb expression (black arrowhead) is evident in 948 
embryos where the compound had no effect (non-hit) and in negative control wells (not shown).  Note 949 
the spot of stain in each embryo, marking expression in the otic vesicle.  Three examples are shown 950 
of wells where compounds were scored as a hit; one of these (Hit 2) was IBMX, represented in the 951 
Spectrum collection.  B.  Pipeline of the compound screening strategy and chemoinformatics analysis.  952 
The left hand side describes the flow of experimental work and the right hand side describes the 953 
complementary chemoinformatics processes.  For details, see the text.   954 
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  956 
Figure 3.  A primary drug screen identified 92 (Tocris) and 205 (Spectrum) putative hit 957 
compounds able to down-regulate vcanb mRNA expression in adgrg6tb233c mutants 958 
A.  Scoring system used to assess vcanb mRNA expression levels in the inner ear of adgd6tb233c 959 
embryos after treatment.  (Ai) vcanb mRNA expression in the untreated/DMSO-treated adgd6tb233c 960 
mutant ear (score 3).  Scores 2 (Aii) and 1 (Aiii) were given to embryos that showed reduced vcanb 961 
mRNA expression to some extent, with 1 given for a stronger down-regulation than 2.  (Aiv) Score 0 962 
was given to embryos where vcanb mRNA levels were equivalent to wild-type levels.  B.  Compounds 963 
were categorised A–G according to the total vcanb score from the three embryos treated.  Colours for 964 
each category correspond to the colours used in panels C–F.  C,E.  Pie charts showing the 965 
distribution of compounds from Tocris (C) and Spectrum (E) libraries in categories A–G.  D,F.  966 
Compounds from Tocris and Spectrum libraries were ordered according to similarities in their 967 
chemical structure and presented as individual dots in polar scatterplots in D and F, respectively, with 968 
jitter (noise) introduced to improve visualisation.  Spectrum library results have a higher level of 969 
clustering as expected from the scaffold analyses.  Scale bar: 50 たm.  970 
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 972 
Figure 3—figure supplement 1.  Scaffold analysis of compound structures in the Tocriscreen 973 
Total and Spectrum libraries 974 
Two different methods were used to remove side chains and determine the core structures of each 975 
compound.  Scaffolds were then compared and a histogram produced with the number of molecules 976 
per scaffold.  The histograms on the left use Bemis and Murcko scaffolds (Bemis and Murcko, 1996), 977 
an example of which shown at the top.  The histograms on the right were generated using CSK 978 
scaffolds.  The number of scaffolds for each library is shown in the top right of each graph.  An 979 
exemplary BMS scaffold and CSK scaffold (obtained from the same compound) are shown above the 980 
histograms.  981 
982 
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Figure 3—source data 1.  Dendrogram representing structural similarity between library 983 
compounds (Tocris). Dendrogram of the Tocriscreen Total library compounds based on the 984 
similarity matrix between all pairs of compounds (Ward’s method of hierarchical agglomerative 985 
clustering—see Materials and Methods).  Compounds are named by their plate and well ID. 986 
Figure 3—source data 2.  Dendrogram representing structural similarity between library 987 
compounds (Spectrum). Dendrogram of the Spectrum library compounds based on the similarity 988 
matrix between all pairs of compounds.  Compounds are named by their plate and well ID. 989 
Figure 3—source data 3.  Dendrogram representing structural similarity between library 990 
compounds (Combined). Dendrogram of the combined Spectrum and Tocriscreen Total library 991 
compounds based on the similarity matrix between all pairs of compounds.  Compounds are named 992 
by their plate and well ID.  993 




Figure 4.  Retesting and counter screen for mbp expression reveals chemical clustering of hit 997 
compounds 998 
A.  Scoring system used to assess mbp mRNA expression levels around the PLLg of adgrg6tb233c 999 
embryos after treatment.  (Ai)  A score of 3 was given to embryos where mbp mRNA expression was 1000 
similar to wild-type levels.  Black arrowhead: mbp expression around the PLLg. (Aii)  A score of 2 was 1001 
given to embryos that showed weak mbp expression around the PLLg.  (Aiii)  A score of 1 was given 1002 
to embryos with mbp expression identical to that in untreated adgrg6tb233c mutants (absence of mbp 1003 
expression around the PLLg (white arrowhead), with weak expression elsewhere).  (Aiv) A score of 0 1004 
was used to indicate embryos where mbp mRNA expression was absent throughout the PNS. Note 1005 
asterisks mark expression near the three cristae of the ear.  Scale bar: 50 たm.  B,C.  mbp scoring 1006 
system and classification of the compounds. B.  Compounds were categorised according to the mbp 1007 
score sum from three embryos (average from two experiments; six embryos total) and grouped into 1008 
compounds able to rescue mbp expression (score >3.5–9) and unable to rescue mbp expression 1009 
(>1.5–3.5).  A third class of compounds down-regulated both vcanb and mbp (score 0–1.5) and were 1010 
not followed further.  C.  Distribution of the compounds in the different rescue categories after the mbp 1011 
counter screen. D.  Compounds from both libraries are represented as individual dots in a combined 1012 
polar scatterplot (3120 compounds in total; 1013 
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https://adlvdl.github.io/visualizations/polar_scatterplot_whitfield_vcanb.html).  Compounds were 1014 
ordered according to similarities in their chemical structure and placed in concentric circles according 1015 
to the category A–G they were assigned to after the primary screen, with jitter (noise) introduced to 1016 
improve visualisation.  E.  Polar scatter plot of the 91 hit compounds that passed the first retest and 1017 
were followed up with mbp counter screens; previous scores for the compounds not followed are 1018 
faded.  F.  Polar scatter plot of the final 68 hit compounds (non-faded) after mbp counter screens.  1019 
Bigger dots represent compounds that rescued mbp expression, whereas smaller dots correspond to 1020 
the compounds that did not rescue mbp expression; compounds that downregulated mbp expression, 1021 
or were not followed, are faded.  Wedges on the scatter plot delineate the two clusters of compounds 1022 
with similar structures for which some hits were followed up in further analysis (see text).  The 1023 
positions of IBMX (I) and colforsin (C) are indicated (red arrowheads). G. Overview of the hit selection 1024 
process.  The length of the horizontal bars is proportional to the number of hit compounds taken 1025 
through to each stage.  Data for the Tocris library are on the left-hand side; data for the Spectrum 1026 
library are on the right-hand side.  The proportion of compounds in hit categories A, B and C are 1027 
shown using the same colour scheme as in Fig. 3, with the top bar representing the number of hits 1028 
from the primary screen listed in Fig. 3B.  The second bar shows the number of compounds that were 1029 
cherry-picked.  The average scores from 9 embryos (after retests) is shown in the third bar.  Note that 1030 
some compounds will change category after the retests and the number of category C compounds is 1031 
increased.  Any compounds that failed to rescue in any single retest were also not taken forward 1032 
(fourth bar). The mbp data (E) are represented in fifth and sixth bars. The final bar represents the 1033 
compounds that were unable to rescue the strong fr24 allele. The total number of compounds at each 1034 
stage is shown in the centre. Note * denotes numbers that do not include duplicate compounds.  1035 
Figure 4F interactive version.  Scatter plot of results from the primary screen (adgrg6tb233c vcanb 1036 
rescue) of Tocris and Spectrum libraries combined.  Hover over individual dots for compound identity. 1037 
https://adlvdl.github.io/visualizations/polar_scatterplot_whitfield_vcanb.html 1038 
 1039 
Supplementary file 1.  List of the 89 hit compounds that rescued the expression of vcanb in 1040 
adgrg6
tb233c mutants and were followed up by mbp counter screens.  The table includes the plate and 1041 
well position of each compound, along with known activities and the raw data scores from nine 1042 
adgrg6
tb233c embryos in the vcanb assay (v1–v9), from six adgrg6tb233c embryos in the mbp assay 1043 
(m1–m6) and from three adgrg6fr24 embryos in the fr24 (fr1–3) assay.  Abbreviations: DE, dead 1044 
embryo; ND, no data; S, Spectrum; T, Tocris.  *Deoxygedunin: (Jang et al., 2010); Nobiletin: (Cheng 1045 
et al., 2016); Angolensin (R): (Weisman et al., 2006); Sinensetin: (Kang et al., 2015); Larixol acetate: 1046 
(Urban et al., 2016); Gedunin: (Hieronymus et al., 2006; Subramani et al., 2017). 1047 
 1048 
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 1050 
Figure 5.  Heatmap of the assay results and network analysis for 68 compounds identified in 1051 
vcanb screen 1052 
A.  Heatmap of the assay results for each of the 68 hit compounds.  Each box represents an embryo 1053 
screened in each of the three assays (vcanb, mbp and fr24) as listed at the bottom of the heatmap.  1054 
Each line corresponds to a different compound.  Colours correspond to the scoring system used for 1055 
each screen (0–3), with dark green, a strong hit (rescue of the mutant phenotype); yellow, no rescue; 1056 
white, no data; white with red cross, toxic.  Compounds were sorted based on the average score for 1057 
mbp with strongest rescue at the top.  The bracket indicates the 41 compounds that rescued both 1058 
vcanb and mbp expression in adgrg6tb233c mutants and thus represent putative Adgrg6 pathway 1059 
modulators.  Abbreviations: C, colforsin; I, IBMX.  B.  Network analysis based on structural similarity, 1060 
showing all 3120 compounds from the two libraries.  Compounds that rescued mbp expression are 1061 
shown as larger nodes, while compounds that did not rescue mbp expression are shown as smaller 1062 
nodes.  The colours used for compounds/nodes correspond to categories A–G (as indicated in Figure 1063 
3) and the two clusters of structurally similar compounds highlighted in Figure 4 are also shown here.  1064 
An interactive version of this figure can be accessed and mined at: 1065 
https://adlvdl.github.io/visualizations/network_whitfield_vcanb_mbp/index.html.   1066 
 1067 
Figure 5B interactive version.  Network analysis based on structural similarity, showing all 3120 1068 
compounds from the Tocris and Spectrum libraries.  Compounds that rescued mbp expression are 1069 
shown as larger nodes, while compounds that did not rescue mbp expression are shown as smaller 1070 
nodes.  The colours used for compounds/nodes correspond to categories A–G (as indicated in Figure 1071 
3) and the two clusters of structurally similar compounds highlighted in Figure 4 are also shown here.  1072 
 40
Zoom into individual nodes for Spectrum (S) and Tocris (T) plate number and well identity (cross-1073 
reference to Supplementary file 1). 1074 
https://adlvdl.github.io/visualizations/network_whitfield_vcanb_mbp/index.html.   1075 
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 1077 
Figure 6.  Hit compounds from the vcanb screen vary in their ability to restore mbp expression 1078 
in adgrg6tb233c mutant embryos  1079 
A.  Section of the heatmap in Fig. 5A showing the results for cilnidipine, nifedipine, tracazolate 1080 
hydrochloride and FPL 64176.  B.  Enlargement of the dihydropyridine cluster (cluster 1 in Figs 4G, 1081 
5B), highlighting cilnidipine and nifedipine. Compounds that rescued mbp expression are shown as 1082 
larger nodes, while compounds that did not rescue mbp expression are shown as smaller nodes. The 1083 
relationship of nilvadipine (green circle) to the other compounds in this cluster is also illustrated.  C.  1084 
(i–vii) Lateral images of the inner ear at 4 dpf stained for vcanb by ISH.  (i) Wild-type, (ii) adgrg6tb233c 1085 
mutant treated with DMSO as a control, (iii–vii) treatment of adgrg6tb233c mutants with test compounds 1086 
at 25 µM, with the exception of nilvadipine which was tested at 22.5 µM.  (viii–xiv) mbp mRNA 1087 
expression of embryos treated as indicated above.  Black arrowheads indicate mbp expression 1088 
around the PLLg; white arrowhead in (ix) indicates the position of the PLLg in the untreated mutant, 1089 
lacking mbp expression.  Nifedipine, cilnidipine, tracazolate hydrochloride and nilvadipine all rescued 1090 
mbp expression around the PLLg, while FPL 64176 did not rescue mbp expression around the PLLg 1091 
so efficiently.  (xv–xix) Representation of the chemical structures of the five compounds tested.  Scale 1092 
bar in (i), 50 µm (applies to i-vii); scale bar in viii, 50 µm (applies to viii–xiv).  1093 
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 1095 
Figure 7.  Selected hit compounds rescue the adgrg6tb233c mutant ear phenotype in a dose-1096 
dependent manner 1097 
adgrg6tb233c homozygous embryos were exposed to a 1.5-fold dilution series of 1098 
concentrations (ranging from 0.3 た‒ to 33.7 た‒), tailored to the toxicity of nifedipine, cilnidipine, 1099 
tracazolate hydrochloride and FPL 64176. IBMX (50 たM and/or 100 たM) was used as a positive 1100 
control; DMSO (1%) was used as a negative control. Embryos were treated between 60–110 hpf prior 1101 
to fixation and analysis for vcanb expression by whole-mount in situ hybridisation. Embryos were 1102 
scored in accordance with two scoring systems, in order to assess the localisation (A) and the 1103 
intensity (B) of vcanb ISH staining.  A.  (i–iv) Scoring system used to assess the number of 1104 
projections (p) with vcanb ISH staining. (v–viii) Charts showing the number of embryos that scored 0p, 1105 
1p, 2p, or 3p.  B.  (i–iv) Charts showing the number of embryos that scored 0, 1, 2, or 3, according to 1106 
the scoring system shown in Fig. 3A.  C.  (i–vi) Live DIC images of 110 hpf (or 90 hpf for FPL 64176-1107 
treated embryos) adgrg6tb233c mutants treated with the compounds shown above. Dorsal views with 1108 
anterior to the left.  (i’–vi’) Lateral views of the inner ear of the embryos depicted in i–vi, showing 1109 
rescue of pillar fusion (arrowheads) following treatment.  D.  Measurements of the ear-to-ear width 1110 
were taken from live embryos mounted dorsally and photographed at a focal plane that highlighted 1111 
the largest visible dimensions (see Fig. 7—Figure supplement 2). Error bars represent the 1112 
mean ± standard deviation. Combined data from two experimental repeats. Scale bars: 50 たm. 1113 
 1114 
Figure 7D—source data 1 1115 
Source data for ear width measurements. 1116 
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 1117 
Figure 7—figure supplement 1.  Additional dihydropyridines are able to downregulate otic 1118 
vcanb expression in adgrg6tb233c mutant embryos 1119 
 1120 
A.  Adapted dihydropyridine cluster including compounds not represented in the Tocris or Spectrum 1121 
collections.  The new compounds tested are shown as green circles.  Nemadipine-A falls just below 1122 
the threshold of the network analysis performed, illustrated by the dotted line connecting to its closest 1123 
related compound. B.  Dose-responsive activity of the dihydropyridines in the vcanb assay.  (i-xii) 1124 
Lateral views of the inner ear at 4 dpf stained for vcanb by ISH; anterior to the left.  Controls: (i) wild-1125 
type, untreated; (vii) adgrg6tb233c mutant treated with DMSO as a negative control; (xii) adgrg6tb233c 1126 
mutant treated with 100 µM IBMX as a positive control.  (ii-vi) Treatment of adgrg6tb233c mutants with 1127 
test compounds at a low concentration (25–33.8 µM), (viii-xi) treatment of adgrg6tb233c mutants with 1128 
test compounds at a high concentration (40–50.6 µM), (xiii-xvii) Representation of the chemical 1129 







Figure 7—figure supplement 2.  Normalisation of ear width with respect to size of the head 1136 
A.  Live DIC image of an adgrg6tb233c mutant embryo at 110 hpf, mounted dorsally with anterior to the 1137 
left, showing the parameters A, B and C (as defined in the figure) used to calculate the normalised ear 1138 
width.  This value was used to assess how the ear swelling is affected after treatment with different 1139 
compounds.  B.  Table showing the strictly standardised mean difference (SSMD) values for each 1140 
treatment group in respect to the vehicle control (adgrg6tb233c, 1% DMSO), as a means of assessing 1141 
the size of compound effect at different concentrations. SSMD scores >2 indicate a strong effect (pale 1142 
orange); SSMD scores >3 indicate a very strong effect (dark orange).  1143 
 1144 
Figure 7—figure supplement 2—source data 1 1145 





Figure 7—figure supplement 3.  LD50 curves from the treatment of wild-type embryos from 60–1150 
110 hpf 1151 
Sixteen LWT wild-type embryos, each kept in a separate well of a 96-well plate, were treated with 1152 
each of the following concentrations: 5, 10, 20, 40, 60, 80 and 100 たM, from 60 to 110 hpf.  At the end 1153 
of the treatment, the number of alive versus dead embryos was counted and the mortality percentage 1154 
was plotted against concentration.  PRISM LD50, a nonlinear fit algorithm, was used to fit the curves 1155 
for tracazolate hydrochloride (A), FPL 64176 (B), nifedipine (C) and cilnidipine (D).  The LD50 was 1156 
calculated as the concentration at which 50% of the embryos were dead. 1157 
 1158 
Figure 7—figure supplement 3—source data 1 1159 
Source data for the mortality counts shown in Figure 7—figure supplement 3. 1160 
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 1162 
Figure 8.  Assay for rescue of the fr24 strong allele distinguishes compounds likely to rescue 1163 
downstream, or at the level of, the Adgrg6 receptor 1164 
A.  Section of the heatmap in Fig. 5A showing the results for colforsin, dihydrofissinolide, 1165 
deoxygedunin and carapin-8(9)-ene.  B.  Enlargement of the cluster containing gedunin-related 1166 
compounds (cluster 2 in Figs. 4G and 5B), highlighting deoxygedunin, dihydrofissinolide and carapin-1167 
8(9)-ene.  Compounds that rescued mbp expression are shown as larger nodes, while compounds 1168 
that did not rescue mbp expression are shown as smaller nodes.  C.  (i–x) The inner ear at 4 dpf 1169 
stained for vcanb.  Lateral views; anterior to the left.  Scale bar (applies to panels i–x): 50 µm.  (i) 1170 
adgrg6
tb233c/DMSO mutant control.  (ii – v)  Treatment of adgrg6tb233c mutants with the compounds at 1171 
25 µM indicated was able to rescue the tb233c mutant ear phenotype to variable degrees.  (vi)  1172 
adgrg6
fr24/DMSO mutant control.  (vii–x)  Treatment of adgrg6fr24 mutants with colforsin rescued otic 1173 
vcanb expression in the fr24 allele, whereas treatment with dihydrofissinolide, deoxygedunin and 1174 
carapin-8(9)-ene was unable to rescue the fr24 ear phenotype.  (xi–xiv)  Representation of the 1175 
chemical structure of the four compounds tested.  Note the structural similarity between 1176 
deoxygedunin, dihydrofissinolide and carapin-8(9)-ene.   1177 
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